Impavido (miltefosine) capsules are indicated for the treatment of visceral leishmaniasis caused by *Leishmania donovani*, cutaneous leishmaniasis caused by *Leishmania braziliensis*, *Leishmania guyanensis*, and *Leishmania panamensis*, and mucosal leishmaniasis caused by *Leishmania braziliensis*. The treatment duration is 28 days.
Dosage and Pharmacokinetics of IMPAVIDO
Patients weighing ≥30 kg are to receive either a 50 mg capsule twice daily for 30-44 kg, or a 50 mg capsule three times daily for 45 kg or greater, administered with food to minimize gastrointestinal adverse reactions. Clinical trials evaluated *Leishmania* species based on epidemiological data, with potential geographic variation in response. The efficacy of miltefosine in treating other *Leishmania* species has not been evaluated. Miltefosine is an anti-leishmanial agent with a long half-life (>6 days), resulting in trough plasma concentrations not reaching a steady state. Maximum concentrations were reached before the next dose in many patients. Distribution studies showed widespread uptake in the kidney, liver, and spleen. Human plasma protein binding was 98%. No in vitro oxidative metabolism was observed.
Clinical Trial Results
The drug is contraindicated in patients with Sjögren-Larsson syndrome. A randomized, open-label study in India involving 299 patients treated with **IMPAVIDO** and 99 patients treated with amphotericin B deoxycholate demonstrated initial cure rates of 98% in both arms. At 6 months, 29.5% of **IMPAVIDO** recipients and 12.1% of amphotericin B recipients continued to have signs and symptoms, attributed to alternative diagnoses in many cases. Final cure rates were 94% for **IMPAVIDO** and 97% for amphotericin B, with 3.0% of **IMPAVIDO** patients experiencing relapse at 6 months.